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Renal effects of angiotensin H receptor blockade in normotensive
subjects. Several new non-peptide, orally active, angiotensin II receptor
antagonists have recently been developed which enable to block the
renin-angiotensin system at the AT1 receptor site. In contrast to angio-
tensin converting enzyme (ACE) inhibitors, these antagonists do not
interfere with the metabolism of kinins. The effect of these agents on renal
function may thus potentialy differ from those of ACE inhibitors. There-
fore, the renal pharmacology of various angiotensin II receptor antago-
nists has been examined in normotensive subjects. In normotensive
subjects, losartan and irbesartan have been shown to have no effect on
glomerular filtration rate and to induce either no change or a modest
increase in renal blood flow. These results were confirmed thereafter in
hypertensive patients where losartan produced a renal vasodilation with
no change in glomerular filtration. In healthy subjects, both losartan and
irbesartan induce an acute increase in urinary sodium excretion. The
natriuretic response to losartan is proportionally more important during
salt-depletion. In contrast to other angiotensin II receptor antagonists,
losartan has a unique property to increase uric acid excretion. In this paper
we show that this property is due to the potent inhibitory effect of the
parent compound of losartan on the urate/anion transport in the human
renal proximal tubule.
In the last 15 years, blockade of the renin-angiotensin system
with angiotensin converting enzyme (ACE) inhibitors which pre-
vent the formation of angiotensin II (Ang II), has proven to be a
successful treatment of hypertension and congestive heart failure
[1, 2]. In contrast to other antihypertensive agents, ACE inhibitors
have also been shown to be particularly effective in retarding the
development of diabetic and non-diabetic nephropathy in animals
as well as in humans [3, 4]. The beneficial effects of ACE
inhibitors on renal function have been attributed mainly to the
inhibition of the renal effects of Ang II, this latter peptide being
an important modulator of renal hemodynamics and sodium
excretion. However, the contribution of the blockade of bradyki-
nm degradation to the renal effects of ACE inhibitors still remains
a matter of debate [5].
Today, several new Ang II receptor antagonists have been
developed which enable to block the renin-angiotensin system at
the AT1 receptor site [6]. In contrast to ACE inhibitors, these
specific and selective receptor antagonists are not expected to be
associated with any effects related to the inhibition of kininase II
or with an increase in prostaglandins. Thus, although ACE
inhibitors and Ang II receptor antagonists both block the renin-
angiotensin system, their influence on renal hemodynamics and
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urinary electrolyte excretion and hence their ability to protect the
kidney might possibly differ. In several recent studies, the renal
effects of various Ang II receptor antagonists have been examined
in normotensive subjects as well as in hypertensive patients with
chonic renal failure. The purpose of the present paper is to review
and discuss these data. In addition, new data will be provided
regarding the mechanism of the uricosuric effect of losartan.
Renal hemodynamic effects of Ang II receptor antagonists
The infusion of low-doses of Ang II in normotensive subjects
causes an increase in blood pressure associated with a marked fall
in renal plasma flow (RPF), hardly any change in glomerular
filtration rate (GFR) and an increase in filtration fraction [7].
Conversely, administration of an ACE inhibitor has been shown in
normal subjects and in hypertensive patients to increase RPF with
little if any effect on GFR; hence filtration fraction decreases [8,
9].
During recent years, the influence of Ang II receptor blockade
on renal hemodynamics has been reassessed in vitro as well as in
experimental studies using the newly developed receptor antago-
nists. Thus, losartan has been shown in the isolated perfused
kidney to antagonize the Ang TI-induced increase in renal vascular
resistance and to block both the afferent and efferent renal
arteriolar effects of angiotensin II [10, 11]. In normotensive and
hypertensive animals, losartan enhances renal blood flow (RBF)
and induces either no change or an increase in GFR, thereby
suggesting that Ang II antagonists have similar effects on renal
hemodynamics as ACE inhibitors [12—14]. In the dehydrated rat,
however, Kon et al have found different renal hemodynamic
responses to ACE inhibition and Ang II receptor blockade [5].
Indeed, the Ang II antagonist induced an increase in single-
nephron GFR and a fall in both afferent and efferent arteriolar
resistance, whereas the ACE inhibitor lowered single-nephron
GFR via a reduction in efferent arteriolar tone with no change in
afferent arteriolar resistance [5]. In addition, a specific antagonist
of bradykinin reversed the decrease in efferent arteriolar resis-
tance and the fall in intraglomerular pressure in ACE inhibitor
treated rats, whereas it had no effect when added on top of the
Ang II antagonist. These latter data thus support the idea that
bradykinin contributes to the renal hemodynamic effects of ACE
inhibitors and that the actions of ACE inhibitors and Ang II
antagonists are not entirely comparable.
The systemic and renal hemodynamic effects of Ang II receptor
antagonists have also been investigated in healthy subjects. Be-
cause ACE inhibitors are known to have more pronounced effects
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during salt depletion [8], the renal impact of a single dose of 100
mg of losartan has been evaluated in normotensive volunteers
maintained alternatively on a low-sodium (50 mmol/day) and on a
high-sodium (200 mmol/day) diet using a cross-over design [15].
In this study, losartan induced no change in blood pressure, GFR
or RBF in either conditions of salt intake. The lack of blood
pressure changes and renal vasodilation during salt-depletion
appeared particularly surprising, but can be explained by the
experimental conditions. Indeed, prior to the administration of
losartan, the volunteers received a substantial water load (12
mi/kg) to ensure an adequate urine flow rate and avoid bladder
catheterization. A subsequent analysis of the data has revealed
that acute water loading per se can modify the activity of the
renin-angiotensin system expected from a given salt diet [16].
Therefore, acute water loading has partially blunted the rise in
plasma angiotensin II levels expected to occur with the low-salt
diet, thereby reducing the contribution of the renin-angiotensin
system to the maintenance of blood pressure, renal vascular tone
and thus renal perfusion [16].
In support of this hypothesis, a fall in blood pressure associated
with a modest increase in RBF and no change in GFR, and
consequently a decrease in filtration fraction, was found in
normotensive subjects after the administration of irbesartan,
another Ang II receptor antagonist [17]. These volunteers were
studied in moderately salt-depleted conditions (100 mmol sodium/
day) and received only a 5 mI/kg water load. A fall in blood
pressure has also been reported with losartan in salt- and water
depleted subjects [18]. Finally, in still another study, losartan and
enalapril have been shown to cause similar increases in RPF with
no change in GFR in normotensive subjects [19].
So far, the renal hemodymanic effects of Ang II receptor
antagonists have not yet been examined in hypertensive patients
with a normal renal function. In a small group of hypertensive
proteinuric patients, however, losartan and enalapril have been
shown to induce a comparable increase in RPF and a decrease in
filtration fraction [20]. Although these results need to be con-
firmed in larger group of patients, they suggest that similar
beneficial renal effects can be expected from the administration of
Ang II antagonists and ACE inhibitors.
Natriuretic effects of Ang II receptor blockade in
normotensive subjects
Angiotensin II contributes to the regulation of sodium excre-
tion via its effect on aldosterone secretion which promotes sodium
reabsorption in the distal tubule and through its ability to induce
sodium retention in the proximal tubule. In normal subjects, the
infusion of low doses of Ang II decreases urinary sodium excre-
tion [21], whereas the administration of an ACE inhibitor in-
creases the natriuresis, an effect linked to both a decrease in
proximal and distal sodium reabsorption [9, 22]. As expected, the
natriuretic response to ACE inhibition is more pronounced in
salt-depleted that is, when the renin-angiotensin system is acti-
vated, than in salt-repleted subjects [22].
An increase in urinary sodium excretion has also been reported
with angiotensin II receptor blockade in rats and dogs [12—14].
During in vivo microperfusion in the Munich-Wistar rat, losartan
was found to have a powerful inhibitory effect on bicarbonate,
chloride and water absorption in the SI segment of the proximal
convoluted tubule [23]. Losartan was more potent than captopril
in inhibiting sodium chloride transport in this segment of the
nephron.
In normotensive subjects, the administration of a single 100-mg
dose of losartan has also been shown to increase urinary sodium
excretion [15]. As observed previously with ACE inhibitors, the
natriuretic response to losartan was proportionally more pro-
nounced during salt-depletion. In a second study, the natriuretic
effect of Ang II receptor blockade has been examined on the first
and on the eighth day of irbesartan administration 10 or 50 mg
once a day [17]. On the first day, irbesartan induced a dose-
dependent increase in sodium excretion. A decrease in the
absolute proximal reabsorption rate of sodium could be demon-
strated with the higher dose of irbesartan, suggesting that, in
accordance with previous animal studies [13, 23], the acute
natriuretic effect of the Ang II antagonist is due mainly to a
reduction of proximal reabsorption. Interestingly, the natriuretic
response to irbesartan was comparable after eight days of treat-
ment. These results would indicate that the natriuresis persists
during repeated administration. As neither body weight nor blood
pressure decreased significantly in these subjects after eight days
of treatment, the persistant acute natriuretic effect of the antag-
onist was most likely followed by another phase of sodium reten-
tion during the night when sodium excretion was not measured.
Angiotensin II receptor blockade and uric acid excretion
In a preliminary study, Nakashima et al have observed that
losartan induces an increase in uric acid excretion in healthy
subjects [24]. The uricosuric effect of losartan was most important
during the first four hours after drug intake and was still present
after seven days of drug administration. The increase in uric acid
excretion was associated with a significant decrease in plasma uric
acid levels. Subsequently, the uricosuric effect of losartan was
demonstrated in normotensive subjects studied on a high- and a
low-sodium diet [151. The uricosuric response to losartan was
comparable with both types of sodium diet, suggesting that the
uricosuric effect of this compound is independent of the blockade
of the renin-angiotensin system. Today, we know that the ability of
losartan to increase uric acid excretion is a pharmacological
property of the mother compound mainly. Indeed, infusion of
E-3174, the active metabolite of losartan, does not modify uric
acid excretion [25]. Moreover, this uricosuric property is not
found with other Ang II receptor antagonists [17].
An increase in uric acid excretion has been observed with
several antihypertensive agents including ACE inhibitors and
calcium channel blockers [26]. However, the uricosuric effect of
these agents is generally modest and is not associated with a
significant decrease in plasma uric acid levels. In contrast, the
effect of losartan which increases the fractional excretion of uric
acid from 3 to 25 to 30% is closer to that observed with classic
uricosuric agents such as probenecid [26].
Because the proximal tubule has been shown to be the site of
secretion and reabsorption of uric acid, the mechanism of the
uricosuric effect of losartan has recently been examined in brush-
border membrane vesicles of proximal tubules harvested from
human kidneys by Roch-Ramel and Guisan [27]. These mem-
brane vesicles have been shown to possess a urate/anion ex-
changer and a urate voltage-sensitive transport system responsi-
ble, respectively, for the tubular reabsorption and secretion of
urate in humans [28]. The inhibitory effects of probenecid,
losartan and its active metabolite (E-3174) on [14C]-urate (50 /LM)
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Table 1. Comparative effects of probenecid, losartan and its
active metabolite E-3174 on urate transport in human brush-border
membrane vesicles
Prohenecid Losartao E-3174
['4C1-urate/lactate 130 tLM 14 LM not tested
['4Cj-urate/chloride 150 /.LM 20 /LM 600 /LM
The values represent the concentration of the drug inhibiting 50%
(IC55) of the urate uptake.
uptake were investigated on brush border membrane vesicles
loaded either with 5 m lactate to investigate the interference
with the urate/lactate exchange, or with 40 m'vi ehioride to
examine the impact on the urate/chioride exchange.
As shown in Table 1, the 50% inhibitory concentration (IC) of
losartan for both exchanges is much lower than that of probenecid
indicating that losartan has a higher affinity for the urate ex-
changer than probenecid. The effect of the metaholite of losartan
(E-3174) has been tested only on the urate/chioride exchange. On
this transport system, it appears to have a low affinity as compared
to the mother compound. These results therefore confirm that
losartan is indeed a potent inhibitor of urate reabsorption. A
schematic representation of the site of the losartan interference
with urate reabsorption is shown on Figure 1.
Today, the clinical implications of the uricosuric effect of
losartan are still difficult to appreciate. Because many hyperten-
sive patients have an increased serum uric acid level, the urico-
suric properties of losartan may be beneficial as they may con-
tribute to normalize serum uric acid. In this respect, a recent study
conducted in hypertensive patients has demonstrated that losar-
tan dose-dependently blunts the increase in serum uric acid
induced by 25 mg hydrochlorothiazide [291. However, at least
theoretically, in some clinical conditions, the acute losartan-
induced variations in urine and serum uric acid concentrations
could become a potential source of problems. This could be the
case, for example, in patients with gout where it could trigger a
gout episode, or in dehydrated patients where uric acid stones
could develop if supersaturation concentrations of urinary uric
acid were reached. Although a larger experience is needed to
draw conclusions, the clinical data obtained so far with losartan
seem to indicate that these side effects are rare. Finally, because
of its effect on proximal tubular transport, losartan like probene-
cid could interfere with the renal excretion of drugs. At the
present time, no such drug interaction has been reported but
clinicians should be aware of this possibility and remain vigilant.
Effects of Ang H receptor antagonists on potassium excretion
Blockade of the renin-angiotensin system with ACE inhibitors
generally causes a rise in plasma potassium due to the decrease in
plasma aldosterone levels and the consecutive reduction in uri-
nary potassium excretion. In contrast to ACE inhibitors, losartan
has been shown in some experimental models to increase rather
than decrease potassium excretion [14, 23]. A surprising, transient
increase in potassium excretion has also been observed in normo-
tensive subjects [15]. This effect is only transient and does not
affect plasma potassium levels. Several mechanisms have been
postulated for this kaliuretic response to losartan. Potassium
excretion may result from the increase in sodium delivery to the
distal tubule. Another potential explanation is that potassium
excretion increases in relation with the high concentrations of uric
urate
X=Iactate, ct-ketoglutarate, succinate
3-hydroxybutyrate, acetoacetate, nicotinate, etc...
acid present in the lumen of the distal tubule. In favor of this
hypothesis is the fact that the time courses of the changes in
potassium and uric acid excretion were similar. In addition, a
significant positive relationship has been found between the
changes in urinary potassium and uric acid excretion [26]. As
mentioned, the variations in potassium excretion in normal sub-
jects were modest and are unlikely to be of clinical relevance in
patients. Thus, administration of losartan did not further reduce
plasma potassium levels in hydrochlorothiazide-treated hyperten-
sive patients [291. Moreover, the incidence of increased serum
Type of transport
urate
J
oio
Fig. 1. Schematic representation of the urate/anion exchange occuring in the
renal proximal tubule and of the site of action of probenecid and losartan.
Abbreviation X is: lactate, a-ketoglutarate, succinate, /3-hydroxybutyrate,
acetoacetate, nicotinate, etc.
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potassium (> 0.5 mmol/liter) was not different in patients receiv-
ing losartan or captopril [30].
Conclusions
The evaluation of the renal effects of Ang II receptor antago-
nists in normotensive subjects has demonstrated that specific
blockade of the renin-angiotensin system at the AT1 receptor site
causes rather similar changes in renal hemodynamic and sodium
excretion to those observed with ACE inhibitors, which in addi-
tion interfere with the degradation of kinins. These observations
are corroborated by experimental studies [31, 32] and recent
clinical observations in hypertensive patients with chronic renal
failure [20] suggesting that losartan and enalapril have compara-
ble effects on proteinuria. Studies in healthy subjects have enabled
to reveal the unique pharmacological property of the mother
compound losartan to interfere with uric acid excretion. In the
present study, we show that losartan is a potent inhibitor of the
urate/anion transport in the human renal proximal tubule. This
finding gives first insights on the mechanisms of the uricosuric
effect of losartan. Additional studies should be conducted to
evaluate whether losartan like probenecid interfers with the renal
excretion of drugs.
Reprint requests to Dr. M Bumier, MD., Division of Hypertension, CHUV
1010 Lausanne, Switzerland.
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